Innovative Drug Development in Dermatology
Latest News

February 26, 2013

Brickell announces $7M Series B financing; AMOREPACIFIC Group, the largest cosmetic and aesthetics company in Korea, leads financing and becomes strategic partner.
Read Article (PDF)


Focused on the development of novel therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative, first-in-class therapeutics to satisfy current unmet human needs in the global dermatology markets.



Brickell Biotech, Inc. © 2014 All Rights Reserved.